Aytu BioPharma, Inc. (AYTU)
AYTU moved a median of -0.14% 30 minutes after news, and -0.88% by the close. How AYTU actually reacts to news — the realized, point-in-time move the market made, measured across 172 labeled events over the last three years with zero look-ahead.
AYTU’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 26% | 160 |
| 30-min | -0.14% | 40% | 167 |
| 60-min | 0.00% | 45% | 168 |
| to close | -0.88% | 39% | 170 |
| Middle 50% of AYTU reactions | -1.67% to +0.46% |
|---|---|
| Median reaction (30-min) | -0.14% |
| Measured reactions | 172 |
Half of all Aytu BioPharma, Inc. news events land between -1.67% and +0.46% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when AYTU moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AYTU's baseline. Nothing else.
Recent AYTU events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results | Press release | ACCESS Newswire | -2.14% | -2.56% | |
| Form 10-K AYTU BIOPHARMA, INC For: Jun 30 | SEC filing · Form 10-K | SEC EDGAR | -2.14% | -2.56% | |
| Form 8-K AYTU BIOPHARMA, INC For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | -2.14% | -2.56% | |
| Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026 | Press release | ACCESS Newswire | — | +2.04% | |
| Form 8-K AYTU BIOPHARMA, INC For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | — | +0.46% | |
| Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026 | Press release | ACCESS Newswire | +0.95% | +0.00% | |
| Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 | Press release | ACCESS Newswire | +0.00% | -1.89% | |
| Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results | Press release | ACCESS Newswire | +0.00% | -0.87% | |
| Form 10-Q AYTU BIOPHARMA, INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -0.87% | |
| Form 8-K AYTU BIOPHARMA, INC For: May 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.87% | |
| Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026 | Press release | ACCESS Newswire | +0.00% | -4.26% | |
| Form 8-K AYTU BIOPHARMA, INC For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.11% | |
| Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results | Press release | ACCESS Newswire | -7.60% | -6.00% | |
| Form 10-Q AYTU BIOPHARMA, INC For: Dec 31 | SEC filing · Form 10-Q | SEC EDGAR | -7.60% | -6.00% | |
| Form 8-K AYTU BIOPHARMA, INC For: Feb 03 | SEC filing · Form 8-K | SEC EDGAR | -7.60% | -6.00% | |
| Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026 | Press release | ACCESS Newswire | +0.00% | -1.13% | |
| Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA | Press release | ACCESS Newswire | +2.68% | +2.68% | |
| Aytu BioPharma Recaps Investor Day Held on January 20, 2026 | Press release | ACCESS Newswire | -1.89% | -5.09% | |
| Form 8-K AYTU BIOPHARMA, INC For: Jan 20 | SEC filing · Form 8-K | SEC EDGAR | -1.89% | -5.09% | |
| Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026 | Press release | ACCESS Newswire | -1.48% | +3.38% | |
| Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City | Press release | ACCESS Newswire | -1.12% | +0.38% | |
| Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City | Press release | ACCESS Newswire | +1.45% | -5.00% | |
| Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults | Press release | ACCESS Newswire | -2.44% | -2.51% | |
| Form 8-K AYTU BIOPHARMA, INC For: Dec 10 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.72% | |
| Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference | Press release | ACCESS Newswire | -0.96% | +1.68% | |
| Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025 | Press release | ACCESS Newswire | -1.58% | +12.63% | |
| Aytu BioPharma Announces Patent Term Extension for EXXUA(TM) | Press release | ACCESS Newswire | +2.22% | -3.56% | |
| Form ARS AYTU BIOPHARMA, INC For: Jun 30 | SEC filing · Form ARS | SEC EDGAR | +0.00% | -3.07% | |
| Form DEF 14A AYTU BIOPHARMA, INC For: Dec 10 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -3.07% | |
| Form DEFA14A AYTU BIOPHARMA, INC | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -3.07% | |
| Aytu BioPharma to Present at Upcoming October 2025 Conferences | Press release | ACCESS Newswire | +1.57% | -7.45% | |
| Aytu BioPharma to Present at Upcoming September 2025 Conferences | Press release | ACCESS Newswire | -3.87% | -10.14% | |
| Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM) | Press release | ACCESS Newswire | -5.00% | -6.36% | |
| Form 10-K AYTU BIOPHARMA, INC For: Jun 30 | SEC filing · Form 10-K | SEC EDGAR | -5.00% | -6.36% | |
| Form 8-K AYTU BIOPHARMA, INC For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | -5.00% | -6.36% | |
| Form S-8 AYTU BIOPHARMA, INC | SEC filing · Form S-8 | SEC EDGAR | -5.00% | -6.36% | |
| Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025 | Press release | ACCESS Newswire | +4.33% | +0.43% | |
| Form 8-K AYTU BIOPHARMA, INC For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM) | Press release | ACCESS Newswire | +0.01% | +4.88% | |
| Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM) | Press release | ACCESS Newswire | -0.99% | -1.49% | |
| Form 8-K AYTU BIOPHARMA, INC For: Jun 20 | SEC filing · Form 8-K | SEC EDGAR | -0.99% | -1.49% | |
| Form 8-K AYTU BIOPHARMA, INC For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +0.32% | +2.60% | |
| Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan | Press release | ACCESS Newswire | -0.46% | -7.76% | |
| Form 8-K AYTU BIOPHARMA, INC For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | -0.46% | -7.76% | |
| Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock | Press release | ACCESS Newswire | +0.65% | +29.87% | |
| Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States | Press release | ACCESS Newswire | +0.65% | +29.87% | |
| Form 8-K AYTU BIOPHARMA, INC For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | +3.40% | +5.50% | |
| Form EFFECT AYTU BIOPHARMA, INC | SEC filing · Form EFFECT | SEC EDGAR | +0.65% | +29.87% | |
| Form S-1MEF AYTU BIOPHARMA, INC | SEC filing · Form S-1MEF | SEC EDGAR | +0.65% | +29.87% | |
| Form S-1/A AYTU BIOPHARMA, INC | SEC filing · Form S-1 | SEC EDGAR | +0.65% | +29.87% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AYTU section they belong to.
Where else AYTU is measured.
AYTU earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| EARTH SCIENCE TECH INC (ETST) | 173 | 0.00% | 33% |
| Exicure, Inc. (XCUR) | 173 | 0.00% | 49% |
| Alpine Immune Sciences, Inc. (ALPN) | 171 | +0.05% | 54% |
| NuCana plc - American Depositary Shares (NCNA) | 171 | -1.28% | 40% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Aytu BioPharma, Inc.'s median reaction calculated?
Every labeled AYTU news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 172 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of AYTU's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AYTU's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.